Search research articles
Contact Us
Filters
Showing results (271-280 of 305) with videos related to
Page
of 31
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
June 2, 2024
Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART
Paul Loubet, Jean-Daniel Lelievre, Alexis François, et al.
Clinical Drug Investigation
|
January 16, 2026
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study
Andrew Ustianowski, Myron J Levin, Stephane De Wit, et al.
The Lancet. Rheumatology
|
August 1, 2025
Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial
Jacques Morel, Emmanuelle Dernis, Christian Roux, et al.
The Lancet. Infectious Diseases
|
September 18, 2020
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial
Guy de Bruyn, David L Gordon, Theodore Steiner, et al.
Eclinicalmedicine
|
May 18, 2022
Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
Cécile Janssen, Marine Cachanado, Laetitia Ninove, et al.
The New England Journal of Medicine
|
April 20, 2022
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
Myron J Levin, Andrew Ustianowski, Stéphane De Wit, et al.
Communications Medicine
|
January 18, 2025
Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants
Odile Launay, Rachna Gupta, Tifany Machabert, et al.
BMC Infectious Diseases
|
September 28, 2024
Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants
Mathieu Chalouni, Paul Loubet, Edouard Lhomme, et al.
Infectious Diseases Now
|
March 17, 2024
Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination
Christine Durier, Laetitia Ninove, Sylvie van der Werf, et al.
Science Translational Medicine
|
February 15, 2013
Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors
Federico Sandoval, Magali Terme, Mevyn Nizard, et al.
Page
of 31
Search research articles
Search
Showing results (271-280 of 305) with videos related to
Sort By:
Page
of 31
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
June 2, 2024
Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART
Paul Loubet, Jean-Daniel Lelievre, Alexis François, et al.
Clinical Drug Investigation
|
January 16, 2026
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study
Andrew Ustianowski, Myron J Levin, Stephane De Wit, et al.
The Lancet. Rheumatology
|
August 1, 2025
Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial
Jacques Morel, Emmanuelle Dernis, Christian Roux, et al.
The Lancet. Infectious Diseases
|
September 18, 2020
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial
Guy de Bruyn, David L Gordon, Theodore Steiner, et al.
Eclinicalmedicine
|
May 18, 2022
Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
Cécile Janssen, Marine Cachanado, Laetitia Ninove, et al.
The New England Journal of Medicine
|
April 20, 2022
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
Myron J Levin, Andrew Ustianowski, Stéphane De Wit, et al.
Communications Medicine
|
January 18, 2025
Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants
Odile Launay, Rachna Gupta, Tifany Machabert, et al.
BMC Infectious Diseases
|
September 28, 2024
Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants
Mathieu Chalouni, Paul Loubet, Edouard Lhomme, et al.
Infectious Diseases Now
|
March 17, 2024
Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination
Christine Durier, Laetitia Ninove, Sylvie van der Werf, et al.
Science Translational Medicine
|
February 15, 2013
Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors
Federico Sandoval, Magali Terme, Mevyn Nizard, et al.
Page
of 31